Cancer Vaccines Are the N.I.H’s Next ‘Big Bet’
After the peak, new reports halved every 13 hours so far - this story is still being covered, so the figure moves as reports arrive.
What it is about
Who published it, and when
9 reports left out of the cascade - too little in common with the story to place
How it spread - 18 original reports
Fri, 9 October 2026
2 reports- Google News - Top Stories14:01
Cancer Vaccines Are the N.I.H’s Next ‘Big Bet’ The New York Times Moderna stock jumps on planned national cancer vaccine effort Yahoo Finance Moderna, Other Vaccine Developer Stocks Rise as NIH Plans to Expedite Cancer Vaccines marketscreener.com CT doctors provide insight on experimental vaccines, drugs providing cancer patients with hope CT Insider PICI Highlights the New Era of Therapeutic Cancer Vaccines Oncodaily
- Google News - Top Stories16:14
Moderna stock jumps on planned national cancer vaccine effort Yahoo Finance See more headlines & perspectives on Google News
Thu, 15 October 2026
1 report- 247wallst.com12:20
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price.
Fri, 16 October 2026
1 report- aol.com15:22
Moderna sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.
Thu, 22 October 2026
9 reports- themarketsdaily.com16:05
Moderna, Danaher, and AbbVie are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that develop products and technologies using biological processes, such as medicines, vaccines, diagnostics, and gene therapies. For investors, these stocks can offer substantial growth potential but often carry significant […]
- Google News - Top Stories19:04first to report
Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media WSJ Experimental mRNA vaccine cuts risk melanoma returns by 42% CNN Moderna shares sink after leaked cancer data missed expectations Financial Times Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report The New York Times A Novel MRNA Cancer Vaccine Helps Reduce the Chances of Melanoma Patients' Tumors Returning U.S. News & World Report
- El País (Spain)19:41
El inyectable ayudó a reducir en un 42% el riesgo de recurrencia del cáncer, resultado que parece haber decepcionado a Wall Street
- ABC (Spain)19:54
Las acciones de la farmacéutica Moderna se hundían hasta un 24% en Bolsa después de que un usuario de la red social X difundiera un informe que muestra que la vacuna contra el melanoma desarrollada junto al laboratorio Merck —conocido en España y Latinoamérica como MSD— no ha cumplido con las expectativas previstas.De esta manera, los títulos caían hasta los 187,6 dólares después de cerrar la pasada jornada en los 245,81 dólares, lo que supone un descalabro del 23,7%.En la citada red social...
- Index.hr (Croatia)20:47
DIONICE Moderne oštro su pale nakon curenja podataka o novoj mRNA terapiji koja za čak 42 posto smanjuje rizik od povrata melanoma kod pacijenata.
- Google News - Top Stories22:12
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% Ars Technica Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report The New York Times Experimental mRNA vaccine cuts risk melanoma returns by 42% CNN Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media WSJ Moderna stock crashes as leaked melanoma data threatens its record August rally Yahoo Finance
- Google News - Top Stories22:15
Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial STAT Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall Reuters Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media WSJ A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning AP News Moderna stock crashes as leaked melanoma data threatens its record August rally Yahoo Finance
- Google News - Top Stories22:24
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results BioPharma Dive Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media WSJ Tempus shares take a hit after Moderna-Merck melanoma data leak Crain's Chicago Business Moderna stock crashes as leaked melanoma data threatens its record August rally Yahoo Finance Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% Ars Technica
- wenxuecity.com23:15
Modernasharesdroppedasmuchas25%onThursdayfollowingtheleakofpartialdataonitscloselywatchedcancervaccinedevelopedwithMerck....
Fri, 23 October 2026
4 reports- Google News - Top Stories03:24
Breakthrough vaccine for the deadliest skin cancer cut risk by almost half The Washington Post Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media WSJ Experimental mRNA vaccine cuts risk melanoma returns by 42% CNN Moderna stock crashes as leaked melanoma data threatens its record August rally Yahoo Finance Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report The New York Times
- geo.tv04:39
Moderna and Merck have said that their mRNA cancer vaccine, when combined with Merck's widely used immunotherapy, cut the risk of melanoma death or recurrence by 42% in a large trial, potentially paving the way for a new era of...
- Google News - Top Stories10:00
Moderna Stock Plummets 18% After Cancer-Vaccine Data Leak Barron's First-of-Its-Kind Vaccine Ushers in New Hope for Cancer Patients The New York Times Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media WSJ A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning Yahoo Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% Ars Technica
- Google News - Top Stories23:00
Moderna’s Cancer Vaccine Success Doesn’t Live Up to Early Hype WSJ Melanoma Vaccine Ushers in New Hope for Cancer Patients The New York Times Moderna stock extends losses as investors digest melanoma vaccine trial data Yahoo Finance ESMO: After leak, Merck and Moderna post phase 3 cancer vaccine data early Fierce Biotech Breakthrough vaccine for the deadliest skin cancer cut risk by almost half The Washington Post
Tue, 27 October 2026
1 report- seekingalpha.com15:30
Moderna (MRNA) stock falls as William Blair downgrades the biotech, citing valuation concerns after a trial win for its Merck (MRK)-parnered cancer shot. Read more here.